Tema Etfs LLC acquired a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,008 shares of the medical research company's stock, valued at approximately $843,000.
A number of other hedge funds have also made changes to their positions in the business. Asset Planning Inc acquired a new position in Exact Sciences in the fourth quarter valued at approximately $40,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Exact Sciences in the 4th quarter valued at about $45,000. AlphaQuest LLC raised its holdings in Exact Sciences by 22,825.0% during the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Exact Sciences during the 4th quarter worth $66,000. Finally, Ostrum Asset Management grew its holdings in Exact Sciences by 28.4% in the fourth quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after purchasing an additional 527 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company's stock.
Exact Sciences Stock Performance
Shares of NASDAQ:EXAS traded up $0.19 during trading on Friday, reaching $56.67. The stock had a trading volume of 835,340 shares, compared to its average volume of 2,583,111. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The stock has a fifty day simple moving average of $47.34 and a two-hundred day simple moving average of $51.96. The firm has a market capitalization of $10.69 billion, a price-to-earnings ratio of -10.17 and a beta of 0.92. Exact Sciences Co. has a 52 week low of $39.97 and a 52 week high of $72.83.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.16. The business had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm's revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.60) EPS. As a group, analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on EXAS. Mizuho began coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price target for the company. Guggenheim reaffirmed a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Barclays boosted their target price on shares of Exact Sciences from $55.00 to $75.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Evercore ISI boosted their price target on shares of Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, Robert W. Baird boosted their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $70.90.
Check Out Our Latest Stock Report on EXAS
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Stories
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
